Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

David A. Middleton
d.middleton@lancaster.ac.uk


Gavin Galasko
dr.galasko@nhs.net


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of HDL cholesterol dysfunction Version 1.0

Study of HDL cholesterol dysfunction Version 1.0

Recruiting

Open to: Female / Male

Age: 18 Years - 70 Years

Medical Conditions

Ischaemic heart diseases
Metabolic disorders


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


High-density lipoprotein – otherwise known as "good cholesterol" - are tiny particles of protein and fats in the bloodstream that help to prevent cholesterol from building up into plaques that clog our arteries. HDL can turn bad in patients with diseased arteries, and in those suffering heart attacks, strokes and diabetes. This so-called dysfunctional HDL is less efficient at removing cholesterol from arteries, and can even increase the progression of heart disease. The aim of this project is to understand exactly what makes HDL turn bad. We will analyse HDL from patients who are at high risk of developing heart disease and who have been confirmed to have plaques in their arteries. We will look at how the make-up of their HDL differs from HDL from people who are at low risk of developing heart disease and find out why their HDL is less efficient at removing cholesterol. We will then prepare model HDL particles that we can study using advanced technology to understand how the different proteins and fats interact with each other to make the particles dysfunctional. We will use the results to develop new tests for dysfunctional HDL that will help to determine the risk of patients developing heart disease.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

22 Mar 2024 31 Dec 2025

Observational

Observational type: Clinical Laboratory Study;



You can take part if:



You may not be able to take part if:


No exclusion criteria will be applied in the first instance. If the study results suggest there are confounding factors, for example, from smoking, type 2 diabetes and pregnancy, we will adapt the participant selection process accordingly. Should this be the case, NHSREC approval will be sought for an amendment to this proposal.


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Blackpool Victoria Hospital
    Blackpool
    Lancashire
    FY3 8NR

Gavin Galasko
dr.galasko@nhs.net


David A. Middleton
d.middleton@lancaster.ac.uk



The study is sponsored by University of Lancaster and funded by BRITISH HEART FOUNDATION .




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details

for Trial ID: CPMS 59866

Last updated 25 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.